September 6–7, 2025, “2025 Conference on Rabies Prevention and Control and the 5th Training Course on Standardized Diagnosis and Treatment of Animal-Related Injuries in Space” The event was successfully held in Beijing. It brought together renowned experts and scholars from across the country in the fields of rabies prevention and control, clinical treatment, and animal‑bite injuries, who engaged in an in-depth discussion on the new challenges and emerging technologies confronting China’s rabies prevention and control efforts. As an innovative domestic manufacturer of human rabies vaccines, Zhuoyi Biotechnology was invited to attend this prestigious gathering and showcased its latest breakthroughs in vaccine safety.

On September 5, the registration day, Zhuoyi Biotechnology welcomed its first batch of distinguished guests. Experts in the vaccine field and representatives from partner service providers from across the country arrived one after another to check in and engage in discussions. Zhuoyi Biotechnology’s staff extended a warm welcome, providing attendees with comprehensive conference materials and attentive services.

Following the opening ceremony on the morning of September 6, the conference moved into its core agenda. Academician Xia Xianzhu from the Haidian No. 26 Retired Cadres Sanatorium of the Beijing Garrison District, Researcher Lu Xuexin from the Chinese Center for Disease Control and Prevention, Director Li Faliang of the Fifth Affiliated Hospital of Zhengzhou University, and Li Hu, head of the canine‑bite clinic at Beijing Luhe Hospital affiliated with Capital Medical University, delivered plenary presentations on topics including the elimination of dog‑to‑human rabies by 2030, the epidemiology and prevention of rabies in China, potential triggers of common adverse reactions, and the selection of rabies vaccines.

At this conference, Li Faliang, Director of the Fifth Affiliated Hospital of Zhengzhou University, delivered a keynote address titled “Special Report: Potential Triggers of Common Adverse Reactions and Selection of Rabies Vaccines,” in which he provided an in-depth analysis of the factors underlying adverse reactions. He emphasized that China’s rabies vaccines are among the best in the world and stressed that vaccine selection should take into account strain homology, manufacturing processes, quality‑control measures, and other relevant factors. He also underscored how technological innovations—such as the use of human‑derived viral strains and the absence of antibiotic additives—have enhanced vaccine safety. Zhuoyi VVM rabies vaccine, as a next‑generation leader in China’s rabies vaccination landscape, demonstrates outstanding safety and is highly trustworthy. Zhuoyi Biologics’ rabies vaccine is produced using low‑passage Vero cells, which are non‑tumorigenic, and contains no added antibiotics, backed by proprietary technology. Its 0.5 mL small‑dose formulation enhances vaccination safety. A next‑generation manufacturing process minimizes impurities and further ensures sterility. The vaccine exhibits a superior adverse‑reaction profile, with high homology to the CTN‑1 strain for enhanced efficacy, while its VVM label provides an additional layer of safety for recipients.

Director Li Faliang particularly emphasized the unique advantages of Zhuoyi Biotech’s VVM rabies vaccine. Zhuoyi Bio is the first domestic company to use VVM‑labeled rabies vaccines. , As a full‑process time‑temperature indicator, the VVM label can precisely track every stage of a vaccine’s journey from the manufacturer to the end user, ensuring that the vaccine is stored and transported within the appropriate temperature range. This helps prevent vaccine degradation caused by temperature excursions, giving recipients greater peace of mind. Meanwhile, This label also facilitates the monitoring of vaccine status by disease control agencies, clinicians, and vaccinators, thereby enhancing overall vaccination safety. Moreover, Zhuoyi VVM rabies vaccine is backed by comprehensive insurance coverage, providing protection against vaccine‑related adverse events, abnormal reactions, vaccination errors, and vaccine‑induced immunization failure, thereby giving both healthcare providers and patients peace of mind.

Director Li Faliang’s presentation was both thorough and easy to understand, enabling attendees to gain a clearer grasp of the common causes underlying adverse reactions to rabies vaccines, while also providing a more comprehensive understanding of the advantages of Zhuoyi VVM rabies vaccine.

During the conference, Zhuyi Bio’s booth was bustling with attendees, who stopped by one after another to engage in lively discussions. The event featured detailed presentations on Zhuyi’s VVM‑compatible rabies vaccine, along with a dedicated interactive experience zone. Participants enthusiastically took part in on‑site activities, collected attractive gifts, and posed for photos with the charming brand mascot, “Zhuo Xiaoyi.” Many expert attendees remarked that this close‑up exchange deepened their understanding of Zhuyi’s vaccine’s technological strengths—particularly its human‑derived viral strain, antibody‑free patent, and VVM labeling—technologies that left a lasting impression.

This year’s Rabies Prevention and Control Conference has successfully established a platform for academic exchange and industry collaboration, offering new ideas and directions to advance rabies prevention and control efforts in China.

Looking ahead, Zhuoyi Biotechnology will steadfastly and steadily advance along this path, continuously refining its products and services. With even higher‑quality vaccine offerings and expert support, we will spare no effort in safeguarding public health. At the same time, we will actively engage in industry dialogue and collaboration, tirelessly striving to elevate China’s rabies prevention and control to new heights, and contributing more of Zhuoyi’s wisdom and strength toward the ambitious goal of eradicating rabies.